{"top_spans": [[0, 0], [1, 1], [2, 3], [3, 3], [6, 7], [6, 8], [6, 11], [9, 11], [12, 12], [13, 13], [13, 20], [16, 19], [21, 21], [23, 28], [30, 30], [31, 31], [31, 34], [31, 40], [32, 34], [32, 40], [38, 40], [41, 41], [41, 46], [42, 42], [48, 51], [53, 53], [55, 55], [64, 64], [75, 77], [75, 79], [78, 78], [79, 79]], "predicted_antecedents": [-1, -1, -1, -1, -1, -1, -1, -1, -1, 8, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 7, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "document": ["teva", "gets", "fda", "committee", "nod", "for", "rituxan", "biosimilar", "filing", "teva", "pharmaceutical", "industries", "limited", "teva", "along", "with", "south", "korean", "partner", "celltrion", "inc", "announced", "that", "the", "fda", "oncologic", "drugs", "advisory", "committee", "has", "voted", "unanimously", "16", "-", "0", "recommending", "approval", "of", "ct", "-", "p10", "their", "proposed", "monoclonal", "antibody", "mab", "biosimilar", "to", "roche", "rhhby", "rituxan", "rituxan", "is", "approved", "to", "treat", "non", "-", "hodgkin", "lymphoma", "nhl", "chronic", "lymphocytic", "leukemia", "rheumatoid", "arthritis", "wegener", "granulomatosis", "and", "microscopic", "fda", "teva", "pharmaceutical", "industries", "ltd", "teva", "pharmaceutical", "industries", "limited", "teva"], "clusters": [[[0, 0], [13, 13]], [[23, 28], [41, 41]]]}